<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jcmm70620" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">J Cell Mol Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id><journal-id journal-id-type="publisher-id">JCMM</journal-id><journal-title-group><journal-title>Journal of Cellular and Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1582-1838</issn><issn pub-type="epub">1582-4934</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407640</article-id><article-id pub-id-type="pmc">PMC12101068</article-id><article-id pub-id-type="doi">10.1111/jcmm.70620</article-id><article-id pub-id-type="publisher-id">JCMM70620</article-id><article-id pub-id-type="other">JCMM-10-2024-130.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Phenotypic Profile of Waldenstr&#x000f6;m Macroglobulinaemia B&#x02010;Cells: Establishment of a Diagnosis Scoring System and Clinico&#x02010;Biological Correlations</article-title></title-group><contrib-group><contrib id="jcmm70620-cr-0001" contrib-type="author" corresp="yes"><name><surname>Sourdeau</surname><given-names>Elise</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3644-1353</contrib-id><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>elise.sourdeau@aphp.fr</email></address></contrib><contrib id="jcmm70620-cr-0002" contrib-type="author"><name><surname>Boccon&#x02010;Gibod</surname><given-names>Cl&#x000e9;mentine</given-names></name><xref rid="jcmm70620-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jcmm70620-cr-0003" contrib-type="author"><name><surname>Corneau</surname><given-names>Aur&#x000e9;lien</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1272-6872</contrib-id><xref rid="jcmm70620-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jcmm70620-cr-0004" contrib-type="author"><name><surname>Costopoulos</surname><given-names>Myrto</given-names></name><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jcmm70620-cr-0005" contrib-type="author"><name><surname>Bravetti</surname><given-names>Clotilde</given-names></name><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcmm70620-cr-0006" contrib-type="author"><name><surname>Armand</surname><given-names>Marine</given-names></name><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcmm70620-cr-0007" contrib-type="author"><name><surname>Chapiro</surname><given-names>Elise</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3427-7596</contrib-id><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcmm70620-cr-0008" contrib-type="author"><name><surname>Nguyen&#x02010;Khac</surname><given-names>Florence</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3107-6668</contrib-id><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcmm70620-cr-0009" contrib-type="author"><name><surname>Davi</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcmm70620-cr-0010" contrib-type="author"><name><surname>Blanc</surname><given-names>Catherine</given-names></name><xref rid="jcmm70620-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jcmm70620-cr-0011" contrib-type="author"><name><surname>Leblond</surname><given-names>V&#x000e9;ronique</given-names></name><xref rid="jcmm70620-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jcmm70620-cr-0012" contrib-type="author"><name><surname>Baron</surname><given-names>Marine</given-names></name><xref rid="jcmm70620-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jcmm70620-cr-0013" contrib-type="author"><name><surname>Roos&#x02010;Weil</surname><given-names>Damien</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7767-755X</contrib-id><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="jcmm70620-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jcmm70620-cr-0014" contrib-type="author"><name><surname>Le Garff&#x02010;Tavernier</surname><given-names>Magali</given-names></name><xref rid="jcmm70620-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jcmm70620-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jcmm70620-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Sorbonne Universit&#x000e9;, Service d'H&#x000e9;matologie Biologique, H&#x000f4;pital Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re APHP</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="jcmm70620-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Centre de Recherche des Cordeliers</named-content>
<institution>Sorbonne Universit&#x000e9;, Universit&#x000e9; Paris Cit&#x000e9;, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="jcmm70620-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Sorbonne Universit&#x000e9;, Service d'H&#x000e9;matologie Clinique, H&#x000f4;pital Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re APHP</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="jcmm70620-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Sorbonne Universit&#x000e9;, INSERM UMS037 PASS, Plateforme de Cytom&#x000e9;trie (CyPS)</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Elise Sourdeau (<email>elise.sourdeau@aphp.fr</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>29</volume><issue seq="260">10</issue><issue-id pub-id-type="doi">10.1111/jcmm.v29.10</issue-id><elocation-id>e70620</elocation-id><history>
<date date-type="rev-recd"><day>04</day><month>5</month><year>2025</year></date>
<date date-type="received"><day>14</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>13</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Cellular and Molecular Medicine</italic> published by Foundation for Cellular and Molecular Medicine and John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JCMM-29-e70620.pdf"/><abstract><title>ABSTRACT</title><p>Waldenstr&#x000f6;m Macroglobulinaemia (WM) is sometimes difficult to differentiate from marginal zone lymphoma (MZL), two entities with overlapping features for which no single marker assessed by multiparameter flow cytometry (MFC) is specific. The aim of this work was to establish a diagnostic phenotypic score for bone marrow (BM) and peripheral blood (PB) WM samples, to differentiate it from MZL and to improve the detection of small circulating WM clones. This study revealed a distinct phenotypic profile between WM and MZL B&#x02010;cells. WM B&#x02010;cells showed decreased expression of CD19, FMC7, CD22, CD27 and increased expression of CD79b and CD13. Supervised and unsupervised MFC analyses were used to define a phenotypic scoring system: a score of 3/6 or greater in BM or 4/7 or greater in PB samples supported the diagnosis of WM (sensitivity of 97.9% and 94.1% and specificity of 80.0% and 93.5%, respectively). These results were validated in a prospective cohort with very high sensitivity and specificity for the two scoring systems. Clinico&#x02010;biological correlations showed that the absence or low expression of CD38 on BM WM B&#x02010;cells was significantly associated with increased BM and PB infiltration (<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 and <italic toggle="no">p</italic>&#x02009;=&#x02009;0.0024 respectively) and <italic toggle="no">CXCR4</italic> mutation (<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). These results demonstrate that MFC can be used to differentiate WM from MZL with a scoring system that can be easily implemented in routine practice.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcmm70620-kwd-0001">CD38</kwd><kwd id="jcmm70620-kwd-0002"><italic toggle="yes">CXCR4</italic></kwd><kwd id="jcmm70620-kwd-0003">phenotypic scoring system</kwd><kwd id="jcmm70620-kwd-0004">splenic marginal zone lymphoma</kwd><kwd id="jcmm70620-kwd-0005">Waldenstr&#x000f6;m Macroglobulinaemia</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="10"/><word-count count="5400"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jcmm70620-ntgp-0001"><fn fn-type="funding" id="jcmm70620-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="equal" id="jcmm70620-note-0002"><p>Elise Sourdeau and Cl&#x000e9;mentine Boccon&#x02010;Gibod share first authorship.</p></fn><fn fn-type="equal" id="jcmm70620-note-0003"><p>Marine Baron, Damien Roos&#x02010;Weil and Magali Le Garff&#x02010;Tavernier share senior authorship.</p></fn></fn-group></notes></front><body id="jcmm70620-body-0001"><sec id="jcmm70620-sec-0001"><label>1</label><title>Introduction</title><p>Waldenstr&#x000f6;m Macroglobulinaemia (WM) is a rare chronic B&#x02010;cell neoplasm. It is characterised by bone marrow (BM) involvement with a tumoral population composed of a continuum of small lymphocytes (Ly), plasmacytoid lymphocytes and plasma cells. These tumour cells secrete a serum monoclonal immunoglobulin M (IgM) that accumulates in the peripheral blood (PB) [<xref rid="jcmm70620-bib-0001" ref-type="bibr">1</xref>]. The clinical and biological presentation of WM patients is heterogeneous, and differential diagnosis with other B&#x02010;cell neoplasms can be challenging, particularly with marginal zone lymphoma (MZL). Indeed, monoclonal IgM component detection is common in MZL, and the <italic toggle="yes">MYD88</italic> L265P mutation, which is found in over 90% of WM patients, can also be detected in some MZL cases&#x000a0;[<xref rid="jcmm70620-bib-0002" ref-type="bibr">2</xref>, <xref rid="jcmm70620-bib-0003" ref-type="bibr">3</xref>]. Conversely, spleen enlargement, which is more commonly associated with MZL, is sometimes observed in WM patients. Therefore, to achieve precise diagnostic characterisation, it is necessary to integrate multiple laboratory approaches, including multiparameter flow cytometry (MFC) in BM and PB. The commonly described phenotype of WM B&#x02010;cells is IgM<sup>+</sup>, CD19<sup>+</sup>, CD20<sup>+</sup>, CD5<sup>&#x000b1;</sup>, CD10<sup>&#x000b1;</sup>, CD23<sup>&#x000b1;</sup>, CD22<sup>+</sup>, FMC7<sup>+</sup>, CD25<sup>+</sup>, CD27<sup>+</sup> and CD103<sup>&#x02212;</sup>, often accompanied by a CD38<sup>+</sup>/CD138<sup>+</sup> plasma cell component [<xref rid="jcmm70620-bib-0004" ref-type="bibr">4</xref>]. However, the expression of either of these markers is not constant. Therefore, no single marker can confirm or exclude a diagnosis of WM or distinguish it specifically enough from MZL. Although a combination of different MFC marker expressions can be very suggestive of WM diagnosis [<xref rid="jcmm70620-bib-0005" ref-type="bibr">5</xref>, <xref rid="jcmm70620-bib-0006" ref-type="bibr">6</xref>, <xref rid="jcmm70620-bib-0007" ref-type="bibr">7</xref>], no precise immunophenotypic scoring system, such as the one that exists for chronic lymphocytic leukaemia, is available for WM [<xref rid="jcmm70620-bib-0006" ref-type="bibr">6</xref>, <xref rid="jcmm70620-bib-0008" ref-type="bibr">8</xref>, <xref rid="jcmm70620-bib-0009" ref-type="bibr">9</xref>, <xref rid="jcmm70620-bib-0010" ref-type="bibr">10</xref>].</p><p>Therefore, we aimed in a large cohort of WM patients to (i) better define the MFC profile of BM WM B&#x02010;cells and (ii) to compare it to immunophenotypic characteristics of MZL B&#x02010;cells in order to design a diagnostic scoring system to better discriminate these two entities. Additionally, we improved the detection of circulating tumour WM B&#x02010;cells through this phenotypic study. Finally, we correlated the BM phenotype of WM B&#x02010;cells with clinical and biological features.</p></sec><sec sec-type="methods" id="jcmm70620-sec-0002"><label>2</label><title>Methods</title><sec id="jcmm70620-sec-0003"><label>2.1</label><title>Patients</title><p>Patients diagnosed with WM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;133) or MZL (<italic toggle="yes">n</italic>&#x02009;=&#x02009;56) at Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re Hospital (Paris, France) were retrospectively included based on medical records and the availability of BM and/or PB immunophenotypic analysis. For WM cases, the diagnosis, treatment initiation and response criteria followed the WHO classification and recommendations from the tenth International Workshop for Waldenstr&#x000f6;m's Macroglobulinaemia (IWWM) [<xref rid="jcmm70620-bib-0011" ref-type="bibr">11</xref>]. This included a systematic BM biopsy at diagnosis. MZL cases consisted of 27 splenic, 28 nodal and one extranodal case. All cases were confirmed histologically by biopsy of either BM, spleen or lymph nodes. We also incorporated 11 MFC analyses from healthy controls, with no prior diagnosis of gammopathy or haematological disease, including normal BM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2) or PB (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9) samples. In total, 55 patients (29 WM and 26 MZL) diagnosed in 2023 and 2024 were then included in a prospective validation cohort. Written consents were obtained in accordance with the declaration of Helsinki and with ethical approval from national (CNIL 2212382) and local (CPP Ile&#x02010;De&#x02010;France 05/21/2014) ethics committees.</p></sec><sec id="jcmm70620-sec-0004"><label>2.2</label><title>Flow Cytometry Analyses</title><p>MFC analyses were performed on erythrocyte&#x02010;lysed BM or blood samples between 2015 and 2024 with the same MFC panel. A seven&#x02010;colour/three&#x02010;tube panel was used for B lymphocyte phenotype assessment: (i) kappa(&#x003ba;)/lambda(&#x003bb;) light chain&#x02010;FITC/PE, CD19&#x02010;PC5.5, CD5&#x02010;PE&#x02010;Cy7, CD79b&#x02010;APC, CD20&#x02010;PB and CD45&#x02010;HV500; (ii) FMC7&#x02010;FITC, CD38&#x02010;PE, CD19&#x02010;PC5.5, CD5&#x02010;PE&#x02010;Cy7, CD23&#x02010;APC, CD43&#x02010;APC&#x02010;AF750 and CD45&#x02010;HV500; (iii) &#x003ba;/&#x003bb; light chain&#x02010;FITC/PE, CD19&#x02010;PC5.5, CD13&#x02010;PE&#x02010;Cy7, CD22&#x02010;APC, CD27&#x02010;BV421 and CD45&#x02010;HV500 (Table&#x000a0;<xref rid="jcmm70620-supitem-0002" ref-type="supplementary-material">S1</xref>). Data were acquired on a standardised FACS Canto II (BD Biosciences) cytometer with a minimal number of 150,000 leukocytes registered, processed on FACS Diva (BD Biosciences) software and analysed using Kaluza software (Beckman Coulter). The percentage and mean fluorescence intensity (MFI) of each marker on clonal and normal residual B&#x02010;cells (for patients) and normal B&#x02010;cells (for control subjects) have been recovered. The threshold of 30% was chosen to consider a B&#x02010;cells antigen positivity expression, except for CD13 for which the threshold was set at 2% as previously published [<xref rid="jcmm70620-bib-0010" ref-type="bibr">10</xref>]. The flow cytometry analysis strategy is described on Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S1</xref>. Analyses were performed by quadrants to distinguish positive and negative markers (for the flow cytometry profiles, first part of the results). However, we evaluate clonal B&#x02010;cells and marker positivity in the entire pathological B&#x02010;cell population when considering the scoring systems. Unsupervised MFC analyses were performed using Omiq and R software (version 4.0.3). Principal component analysis (PCA) was performed on the 86 BM WM samples used for immunophenotypic analysis. The results demonstrated the absence of a batch effect despite the analysis of samples collected across several years (Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S2</xref>), thereby facilitating the comparison of results across different time points.</p></sec><sec id="jcmm70620-sec-0005"><label>2.3</label><title>Cytogenetic and Molecular Analyses</title><p>Chromosome banding analyses were performed according to usual techniques [<xref rid="jcmm70620-bib-0012" ref-type="bibr">12</xref>]. All karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN 2020). FISH was performed on interphase nuclei and metaphases, following standard procedures and using specific probes: ATM(11q22), TP53(17p13.1), BCL2(18q21), D12Z1(12p11&#x02010;q11), D13S319(13q14), LAMP1(13q34), D6Z1(6p11&#x02010;q11)/SEC63(6q21)/MYB(6q23) and FIP1L1/CHIC2/PDGFRA(4q12) deletion/fusion.</p><p>Genomic DNA was extracted using the QiAamp DNA Micro Kit (Qiagen) from non&#x02010;sorted BM samples. Assessment of <italic toggle="yes">MYD88</italic> and <italic toggle="yes">CXCR4</italic> mutations was performed by either restriction fragment length polymorphism, allele&#x02010;specific polymerase chain reaction or next generation sequencing [<xref rid="jcmm70620-bib-0013" ref-type="bibr">13</xref>].</p></sec><sec id="jcmm70620-sec-0006"><label>2.4</label><title>Statistical Analyses</title><p>All statistical analyses were performed with appropriate tests using GraphPad Prism 9 (version 9.0.0) or STATA (version 14.0) software. Phenotypic characteristics were compared using Mann&#x02013;Whitney tests and correlations assessed with the Spearman test. Multivariate analyses were performed by logistic regression. Performance of BM and PB scoring systems has been determined by using nonparametric ROC curves, with area under the curve (AUC), sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). The optimal decision threshold was chosen by the maximum of the Youden index. Variable importance analysis was performed to rank variables by predictive power according to the Random Forest algorithm. Clinical and phenotypical correlations were realised for 114 WM patients with GraphPad Prism and STATA software. <italic toggle="yes">p</italic>&#x02010;values below 0.05 were considered statistically significant (*<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.05; **<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.01; ***<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.001 and ****<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.0001).</p></sec></sec><sec sec-type="results" id="jcmm70620-sec-0007"><label>3</label><title>Results</title><sec id="jcmm70620-sec-0008"><label>3.1</label><title>Flow Cytometry Profile of <styled-content style="fixed-case" toggle="no">BM</styled-content>
<styled-content style="fixed-case" toggle="no">WM</styled-content> B&#x02010;Cells</title><p>We first evaluated the BM MFC analyses of 86 WM patients to define their immunophenotypic profiles more accurately. The mean BM clonal B&#x02010;cell infiltration, assessed by MFC, was 45% (range, 2&#x02013;92) of total lymphocytes. As expected, clonal B&#x02010;cells from WM patients consistently expressed the pan&#x02010;B markers CD19, CD20, CD22 and CD79b and a restricted light chain with a predominance of &#x003ba; (79% of patients) over &#x003bb; cases. CD5, CD23 and CD43 were mostly negative, found in 9%, 18% and 22% of patients, respectively. The expression of FMC7, CD38 and CD27 was widely heterogeneous among patient samples. Finally, CD13 was expressed in two&#x02010;thirds of patients when applying the previously described 2% threshold of positivity (Figure&#x000a0;<xref rid="jcmm70620-fig-0001" ref-type="fig">1A</xref>). Then, we assessed antigen expression modulations by comparing MFI data of clonal B&#x02010;cells from WM patients with those of mature B&#x02010;cells from healthy controls (Figure&#x000a0;<xref rid="jcmm70620-fig-0001" ref-type="fig">1B</xref>, Table&#x000a0;<xref rid="jcmm70620-supitem-0002" ref-type="supplementary-material">S2</xref>), for all positive markers, except CD13, which is not expressed on normal B&#x02010;cells. In comparison to healthy controls, WM B&#x02010;cells exhibited stronger expression of CD79b (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001), while consistently lower expression of CD19, CD22, FMC7 and CD27 in WM was observed (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0089, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0035 and <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, respectively) (Table&#x000a0;<xref rid="jcmm70620-supitem-0002" ref-type="supplementary-material">S3</xref>). There was no significant difference in CD20 and CD38 MFI expression. Light chain MFI expression was evaluated by comparing WM B&#x02010;cells to residual paired normal B&#x02010;cells when available. WM B&#x02010;cells expressed strongly either &#x003ba; or &#x003bb; light chain (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 and <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, respectively) (Figure&#x000a0;<xref rid="jcmm70620-fig-0001" ref-type="fig">1C</xref>), consistent with increased expression of co&#x02010;receptor CD79b. The most common immunophenotypic expression profile of WM B&#x02010;cells can be summarised as follows: &#x003ba; or &#x003bb; strong light&#x02010;chain restriction, CD19/CD22<sup>+weak</sup>, CD20<sup>+</sup>, CD79b<sup>+strong</sup>, FMC7/CD27<sup>&#x000b1;weak</sup>, CD13/CD38<sup>&#x000b1;</sup> and CD5/CD23/CD43<sup>&#x02212;</sup>. However, some markers, namely FMC7, CD38, CD27 and CD13, showed heterogeneous expression on WM B&#x02010;cells.</p><fig position="float" fig-type="FIGURE" id="jcmm70620-fig-0001"><label>FIGURE 1</label><caption><p>Comparison of antigen expression on B&#x02010;cells between healthy controls (<italic toggle="yes">n</italic>&#x02009;=&#x02009;11) and WM patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;86). (A) Repartition of percentage antigen expression on normal B&#x02010;cells (control subjects) compared to clonal BM WM B&#x02010;cells (WM patients). For each marker, data are represented with control subjects on the left (violet points) and WM patients on the right (red points). (B) MFI of antigen expression on normal B&#x02010;cells (control subjects) compared to clonal BM WM B&#x02010;cells (WM patients). For each marker, boxplot with the median and the interquartile range of MFI are represented with control subjects on the left (violet points) and WM patients on the right (red points). (C) Boxplot with the median and the interquartile range of MFI of light chain restriction expression on clonal BM WM B&#x02010;cells compared to residual normal B&#x02010;cells. *<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.05; **<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.01; ***<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.001 and ****<italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.0001.</p></caption><graphic xlink:href="JCMM-29-e70620-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="jcmm70620-sec-0009"><label>3.2</label><title>Comparison of Flow Cytometry Profiles Between <styled-content style="fixed-case" toggle="no">WM</styled-content> and <styled-content style="fixed-case" toggle="no">MZL</styled-content> B&#x02010;Cells</title><p>To improve differential diagnosis with MZL, we then compared MFC data from 40 MZL samples to those of the 86 BM WM samples described above. No differences were observed between WM and MZL cells regarding &#x003ba; versus &#x003bb; light chain restriction (5:1) and the strong expression of light chain expression. Univariate analyses revealed differential expression of several surface antigens between WM and MZL, including CD19, CD20, CD79b, CD5, CD43, CD38, FMC7, CD22, CD27 and CD13 (Figure&#x000a0;<xref rid="jcmm70620-fig-0002" ref-type="fig">2A</xref>). On a biparametric dot&#x02010;plot, we noticed a differential FMC7/CD38 B&#x02010;cell distribution between WM and MZL with a trend towards overexpression of FMC7 and underexpression of CD38 on MZL B&#x02010;cells (Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S3A</xref>). A logistic regression was performed on significant univariate analysis markers to identify the most relevant antigens for discriminating between WM and MZL. The percentage expressions of CD43 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.012), CD38 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.013) and CD13 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.015) were found to be higher in WM than in MZL, while FMC7 expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001) was significantly lower in the WM group. Additionally, the MFI of CD22 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.011) and CD27 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) were significantly weaker in WM than in MZL clonal B&#x02010;cells (Figure&#x000a0;<xref rid="jcmm70620-fig-0002" ref-type="fig">2B</xref>). A random forest model and a PCA confirmed these data with a discriminant role for the four parameters FMC7, CD22, CD27 and CD13 (Figure&#x000a0;<xref rid="jcmm70620-fig-0002" ref-type="fig">2C,D</xref>). The predictive algorithm correctly classified 83 out of 86 (97%) patients in the WM group and 33 out of 40 (83%) patients in the MZL group based on the selected markers, including percentages of CD43, FMC7, CD38, CD13, and MFI of CD19, FMC7, CD22, CD27 and CD79b. Finally, we analysed immunophenotypic data from 56 WM patients and 34 MZL patients using Omiq software. This unsupervised MFC analysis involved dimensionality reduction (using t&#x02010;SNE) and clustering (using FlowSOM). The results confirmed our previous findings of a distinct profile between WM and MZL (Figure&#x000a0;<xref rid="jcmm70620-fig-0002" ref-type="fig">2E</xref>, Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S4</xref>). Once again, the most significant differences were observed in the fluorescence intensity of FMC7 and CD22 antigens, which were higher in the MZL group than in the WM group.</p><fig position="float" fig-type="FIGURE" id="jcmm70620-fig-0002"><label>FIGURE 2</label><caption><p>Comparison of antigen expression on WM patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;86) and MZL patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;40). (A) Heatmap of median phenotypic markers expression (percentages and MFI) with the corresponding <italic toggle="yes">p</italic>&#x02010;values. (B) Logistic regressions on significant univariate analysis markers. <italic toggle="yes">z</italic> corresponding to the regression coefficient. (C) Performance of the predicted model by the Random Forest algorithm. Representation of the importance of each variable in model prediction according to the Gini index. The top four parameters ranked are based on the mean decrease in Gini coefficient (a measure of homogeneity from 0 [homogeneous] to 1 [heterogeneous]). (D) PCA on phenotypic significant results for CD43, CD38, FMC7 and CD13 percentages and CD19, CD79b, FMC7, CD27 and CD22 MFI between WM patients (red triangles) and MZL patients (blue points). The two largest triangle and point represent the centers of gravity of each patients group. Concentration ellipse contains 50% of the individuals. (E) (a) t&#x02010;SNE analysis of CD19<sup>+</sup> cells. Cells are automatically separated into spatially distinct subsets according to the combination of markers that they express. t&#x02010;Mapping were generated using all markers. The settings run were: Iterations (2000), perplexity (50) and theta (0.5). The upper t&#x02010;SNE corresponds to panel with FMC7, CD38, CD19, CD5, CD23, CD43 and CD45 (tube 2), the lower t&#x02010;SNE corresponds to panel with CD19, CD5, CD22, CD27, CD45, CD13, kappa/lambda light chain (tube 3). The t&#x02010;SNE maps are presented based on 2 clusters: For tube 2, cluster 1 does not express the FMC7 marker, while cluster 2 does; for tube 3, cluster 1 does not express the CD22 marker, while cluster 2 does. (b) Violin plot showing the MFI of FMC7 for tube 2 (top row) and the MFI of CD22 for tube 3 (bottom row) based on the 2 clusters. (c) Proportion of clusters based on MZL and WM for tube 2 (top row) and for tube 3 (bottom row).</p></caption><graphic xlink:href="JCMM-29-e70620-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="jcmm70620-sec-0010"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">WM</styled-content>/<styled-content style="fixed-case" toggle="no">MZL</styled-content> and <styled-content style="fixed-case" toggle="no">MFC</styled-content> Scoring Systems</title><p>We have developed a WM BM&#x02010;based immunophenotypic scoring system to differentiate WM from MZL. The system is based on the six most relevant parameters (Table&#x000a0;<xref rid="jcmm70620-tbl-0001" ref-type="table">1</xref>), including FMC7, CD22, CD27 intensity expression and CD13 percentage. Additionally, CD79b MFI was also included due to its importance in highlighting WM cells in association with CD22. The CD79b/CD22 MFI ratio was significantly higher on WM than MZL B&#x02010;cells (8.3 vs. 1.6, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S3B</xref>). The final parameter, CD19, was useful in distinguishing WM and MZL patients due to its weaker expression in WM (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0006). One point was given for each marker except for CD79b, for which one point was given only for strong CD79b expression in the case of CD22<sup>+weak</sup>. We chose not to include CD38 in our scoring system due to its highly heterogeneous expression among WM patients. The decision threshold for this score was determined on 97 WM patients and 10 MZL patients. ROC curve (AUC&#x02009;=&#x02009;0.9742) indicated that a score greater than or equal to 3/6 was in favour of WM with the best Se (97.9%) and Sp (80.0%) (Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3A</xref>). Similarly, PPV was equal to 97.9% and NPV to 80.0%. Only two WM patients had a score equal to 2 points (Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3B</xref>). All except two patients with MZL had a score equal to less than 3 points. These two MZL patients had a strong expression of FMC7, which supports this diagnosis. Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3C</xref> illustrates the application of the score to a 6&#x02010;point BM sample from a patient with WM.</p><table-wrap position="float" id="jcmm70620-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Bone marrow WM/MZL scoring system based on six parameters.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">0 point</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 point</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FMC7 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Negative or weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD22 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD79b expression if CD22<sup>&#x02212;/weak</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Weak or normal</td><td align="center" valign="top" rowspan="1" colspan="1">Strong</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD27 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">Negative or weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD13 percentage</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;2%</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;2%</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="jcmm70620-fig-0003"><label>FIGURE 3</label><caption><p>Performances of the BM and PB WM/MZL scoring systems. (A) ROC curve with Se and 100&#x02010;Sp according to results of BM score. (B) Number of WM and MZL patients according to each result of BM&#x02010;based score. (C) Application of the marrow&#x02010;based score on a WM patient's BM sample. Biparametric dot&#x02010;plots useful to determinate result of the score: WM B&#x02010;cells are in red, residual B&#x02010;cells are in green and T&#x02010;cells in blue. (D) ROC curve with Se and 100&#x02010;Sp according to results of PB&#x02010;based score. (E) Number of WM and MZL patients according to each result of PB&#x02010;based score. (F) Application of the PB score on a WM patient's blood sample. Biparametric dot&#x02010;plots useful to determinate result of the score: WM B&#x02010;cells are in red, residual B&#x02010;cells are in green and T&#x02010;cells in blue.</p></caption><graphic xlink:href="JCMM-29-e70620-g004" position="anchor" id="jats-graphic-5"/></fig><p>Before transposing this BM based score to the PB compartment, we compared BM with PB MFC analyses for 15 WM patients, for whom paired samples were available (Bland&#x02013;Altman test, data not shown). The expression of FMC7 was significantly higher on PB cells than on BM cells (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0320). However, when comparing PB FMC7 expression (percentage and MFI) on WM and MZL cells, this marker remained significantly decreased in WM compared to MZL (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0007 and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0036, respectively).</p><p>The WM blood MFC scoring system was therefore based on the same six parameters as the BM score, with the addition of the percentage of clonal B&#x02010;cells in the total lymphocytes count (Table&#x000a0;<xref rid="jcmm70620-tbl-0002" ref-type="table">2</xref>). This parameter was significantly lower in WM patients compared to MZL patients (median, 7% vs. 52%; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001). To facilitate its use, a threshold of 10% has been chosen. The PB score decision threshold was determined among 51 WM patients and 46 MZL patients. The ROC curve (AUC to 0.9729) indicated that a score equal to or greater than 4/7 favours WM with the best Se (94.1%) and Sp (93.5%) (Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3D</xref>). Similarly, the PPV was equal to 94.1% and NPV to 93.5%. Only two MZL patients had a cutoff score of 4 points and one patient had a score of 5 points, with a strong expression of FMC7 supporting this diagnosis for two of them. Only three WM patients had a score of 3 points (Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3E</xref>). Figure&#x000a0;<xref rid="jcmm70620-fig-0003" ref-type="fig">3F</xref> presents the application of the PB score on a PB sample from a patient with WM, resulting in a score of 7 points.</p><table-wrap position="float" id="jcmm70620-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Peripheral blood WM/MZL scoring system based on seven parameters.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">0 point</th><th align="center" valign="bottom" rowspan="1" colspan="1">1 point</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Clonal B cells among total lymphocytes percentage</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;10%</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;10%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FMC7 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Negative or weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD22 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal or strong</td><td align="center" valign="top" rowspan="1" colspan="1">Weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD79b expression if CD22<sup>&#x02212;/weak</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">Weak or normal</td><td align="center" valign="top" rowspan="1" colspan="1">Strong</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD27 expression</td><td align="center" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">Negative or weak</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD13 percentage</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;2%</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;2%</td></tr></tbody></table></table-wrap><p>The markers used in the PB&#x02010;based score were helpful in distinguishing and isolating WM B&#x02010;cells from normal B&#x02010;cells. This was particularly useful when circulating tumour cells (CTCs) were present in very low amounts, or when mixed with a majority of normal residual B&#x02010;cells. The CD79b/CD19 biparametric dot&#x02010;plot was especially important in this regard.</p><p>A prospective validation cohort was assembled from samples obtained from 29 WM and 26 MZL patients diagnosed in 2023 and 2024. The application of the BM MFC scoring system to 22 WM and 8 MZL samples demonstrated a sensitivity of 100% and a specificity of 87.5%. Similarly, the application of the blood MFC scoring system to 13 WM and 22 MZL samples exhibited a sensitivity of 92.3% and a specificity of 95.5%.</p></sec><sec id="jcmm70620-sec-0011"><label>3.4</label><title>
<styled-content style="fixed-case" toggle="no">MFC</styled-content>, Clinical and Biological Correlations in <styled-content style="fixed-case" toggle="no">WM</styled-content>
</title><p>Finally, we analysed the correlation between main clinico&#x02010;biological features and phenotypic characteristics in the entire WM cohort. In both univariate and multivariate analyses, no single studied antigen was significantly associated with hyperviscosity syndrome, adenopathy, anaemia, serum IgM level, elevated &#x003b2;2&#x02010;microglobulin, cytogenetic abnormalities, <italic toggle="yes">MYD88</italic> mutation, number of lines of treatment, international prognostic scoring system for WM, treatment response, progression&#x02010;free survival or overall survival (data not shown). However, the absence or low expression of CD38 was significantly correlated with splenomegaly (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0444), high level of lactate dehydrogenase (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01), initiation of a treatment (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0325), a decreased platelet count (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0063), an increased BM (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Figure&#x000a0;<xref rid="jcmm70620-fig-0004" ref-type="fig">4</xref>) and blood tumoral infiltration (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0019) and the presence of a <italic toggle="yes">CXCR4</italic> mutation (S338 and others) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Figure&#x000a0;<xref rid="jcmm70620-fig-0004" ref-type="fig">4</xref>).</p><fig position="float" fig-type="FIGURE" id="jcmm70620-fig-0004"><label>FIGURE 4</label><caption><p>CD38 expression according to WM B&#x02010;cells BM infiltration evaluated by MFC and <italic toggle="yes">CXCR4</italic> mutational status (<italic toggle="yes">n</italic>&#x02009;=&#x02009;74). Patients with a mutation of <italic toggle="yes">CXCR4</italic> are represented with a larger diameter red dot than patients unmutated for <italic toggle="yes">CXCR4</italic> who are represented by a small black dot.</p></caption><graphic xlink:href="JCMM-29-e70620-g002" position="anchor" id="jats-graphic-7"/></fig><p>Furthermore, PCA analysis on 74 WM patients with or without <italic toggle="yes">CXCR4</italic> mutation (S338 and others) revealed a distinct MFC profile with a separation into two groups (Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S5A</xref>). Indeed, associated with the diminution of CD38 expression, <italic toggle="yes">CXCR4</italic>&#x02010;mutated WM clonal B&#x02010;cells demonstrated decreased expression of CD19 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0002), CD79b (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0076), FMC7 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0257) and CD27 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.0280) compared to <italic toggle="yes">CXCR4</italic>&#x02010;unmutated WM clonal B&#x02010;cells (Table&#x000a0;<xref rid="jcmm70620-supitem-0002" ref-type="supplementary-material">S4</xref>, Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S5B&#x02013;C</xref>).</p></sec></sec><sec sec-type="discussion" id="jcmm70620-sec-0012"><label>4</label><title>Discussion</title><p>Due to its heterogeneous clinical and biological presentation, WM can be difficult to distinguish from other monoclonal IgM&#x02010;secreting entities such as MZL. This study revealed that the most common immunophenotypic expression profile of WM B&#x02010;cells is defined by strong light&#x02010;chain restriction, CD19/CD22<sup>+weak</sup>, CD20<sup>+</sup>, CD79b<sup>+strong</sup>, FMC7/CD27<sup>&#x000b1;weak</sup>, CD13/CD38<sup>&#x000b1;</sup>, CD5/CD23/CD43<sup>&#x02212;</sup>. We investigated the potential differences in antigenic expression between WM and MZL cells, two types of lymphoplasmacytic&#x02010;differentiated lymphomas. We identified a distinct MFC profile, characterised by low expression of CD19, FMC7, CD22 and CD27 antigens, strong expression of CD79b, and partial positivity for CD13 on WM tumoral B&#x02010;cells. These results are consistent with those published by Paiva et&#x000a0;al. who used 17 antigenic markers [<xref rid="jcmm70620-bib-0014" ref-type="bibr">14</xref>]. Our findings enabled the development of two scoring systems for the diagnosis of WM. The BM and PB scores were based on six and seven parameters respectively. In the future, a respective threshold of 3/6 and 4/7 could be used for routine diagnosis. These results were validated in a prospective cohort with very high sensitivity and specificity for the two scoring systems.</p><p>Other notable results include the striking association between the presence of a <italic toggle="yes">CXCR4</italic> mutation and the absence or weak CD38 expression on WM B&#x02010;cells, which is also in line with previously published data&#x000a0;[<xref rid="jcmm70620-bib-0015" ref-type="bibr">15</xref>]. We have identified differences between mutated and non&#x02010;mutated <italic toggle="yes">CXCR4</italic> WM patients with low CD38 expression, as well as lower expression of CD19, CD79b, FMC7 and CD27 markers. The study published in 2016 by Poulain et&#x000a0;al. did not describe these phenotypic variations. However, it did reveal lower CD138 expression in the <italic toggle="yes">CXCR4</italic> mutated group (which was not evaluated in the present study), with no difference in CD38 and CD27 expression [<xref rid="jcmm70620-bib-0016" ref-type="bibr">16</xref>].</p><p>Some limitations to our study relate to the changes in the antibodies used in the laboratory over its long timespan, particularly for CD25, whose reactivity varies between clones as well as fluorochromes used (Figure&#x000a0;<xref rid="jcmm70620-supitem-0001" ref-type="supplementary-material">S6</xref>). Therefore, although the CD25<sup>+</sup>/CD22<sup>+weak</sup> association has been described as a phenotypic feature of the WM tumour cell, it could not be assessed in this study. Further validation of our findings will also require a prospective, oligo&#x02010; or multicentre study to reduce variability and ensure robustness. This effort is currently underway in France through a national multicentre study. A multicentric approach would also facilitate harmonisation across different MFC platforms, enabling future automation of multi&#x02010;centre data interpretation. Nevertheless, the role of the biologist in interpreting MFC results remains crucial. One of the strengths of our WM scoring system is that it relies on antigen markers that are routinely used and widely available in haematology laboratories performing MFC analysis for B&#x02010;cell lymphomas (CD19, CD79b, CD22, FMC7 and CD27) and myeloid neoplasms (CD13). Furthermore, similar multi&#x02010;marker scoring systems have already been developed and successfully adopted in clinical practice, notably in CLL [<xref rid="jcmm70620-bib-0008" ref-type="bibr">8</xref>] and hairy cell leukaemia [<xref rid="jcmm70620-bib-0017" ref-type="bibr">17</xref>, <xref rid="jcmm70620-bib-0018" ref-type="bibr">18</xref>].</p><p>Improvements in routine MFC techniques with the use of 12/13&#x02010;colour panels could also be beneficial. Thanks to these technical improvements, new cytometers now allow the use of a single tube&#x02010;panel containing all the markers of interest in our study, including CD45, CD19, &#x003ba;, &#x003bb;, CD79b, CD22, CD27, CD13, CD38, FMC7 and CD25. This leaves one or two fluorescence channels free for other markers, depending on the practice of the centre (such as CD180, CD200, LAIR1) [<xref rid="jcmm70620-bib-0019" ref-type="bibr">19</xref>] or the sample type (such as the addition of CD138 for plasma cells detection in BM). One particular candidate of interest is CD180, a related member of the toll&#x02010;like receptor family, which has been found to be overexpressed at the plasma membrane in circulating cells of MZL [<xref rid="jcmm70620-bib-0020" ref-type="bibr">20</xref>, <xref rid="jcmm70620-bib-0021" ref-type="bibr">21</xref>]. This approach will facilitate the detection of CTCs in PB samples [<xref rid="jcmm70620-bib-0022" ref-type="bibr">22</xref>] and aid in distinguishing between WM and MZL B&#x02010;cells. Finally, our results may have potential therapeutic implications. The arsenal of monoclonal antibodies and bispecifics is constantly expanding in B&#x02010;cell malignancies, with increasingly diverse targets such as CD20/CD19/CD22/CD79b. These targets may have different activity on WM or MZL B&#x02010;cells, given the different expression levels observed for some of these markers.</p><p>In conclusion, this work presents an overview of the most distinguishing phenotypic markers between WM and MZL. It highlights the strong value of MFC in distinguishing these two entities. Two scoring systems have been established, one for BM and one for PB samples, which allow for the correct distinction of WM over MZL with a PPV of over 94%. These scores are based on a limited number of markers, each given one point, making them simple to use and easily implementable in routine diagnostics.</p></sec><sec id="jcmm70620-sec-0017"><title>Author Contributions</title><p>
<bold>Elise Sourdeau:</bold> conceptualization (lead), data curation (lead), formal analysis (lead), methodology (lead), project administration (lead), validation (lead), writing &#x02013; original draft (lead). <bold>Cl&#x000e9;mentine Boccon&#x02010;Gibod:</bold> conceptualization (lead), data curation (lead), formal analysis (equal), methodology (lead), project administration (lead), validation (lead), writing &#x02013; original draft (lead). <bold>Aur&#x000e9;lien Corneau:</bold> data curation (equal), formal analysis (equal), writing &#x02013; original draft (supporting). <bold>Myrto Costopoulos:</bold> data curation (equal), methodology (equal), project administration (equal), writing &#x02013; original draft (supporting). <bold>Clotilde Bravetti:</bold> data curation (equal), formal analysis (equal), writing &#x02013; original draft (supporting). <bold>Marine Armand:</bold> data curation (equal), formal analysis (equal), writing &#x02013; original draft (supporting). <bold>Elise Chapiro:</bold> data curation (equal), formal analysis (equal), writing &#x02013; original draft (supporting). <bold>Florence Nguyen&#x02010;Khac:</bold> data curation (equal), formal analysis (equal), writing &#x02013; original draft (supporting). <bold>Fr&#x000e9;d&#x000e9;ric Davi:</bold> writing &#x02013; original draft (supporting). <bold>Catherine Blanc:</bold> writing &#x02013; original draft (supporting). <bold>V&#x000e9;ronique Leblond:</bold> writing &#x02013; original draft (supporting). <bold>Marine Baron:</bold> conceptualization (lead), data curation (equal), formal analysis (equal), methodology (lead), project administration (lead), validation (lead), writing &#x02013; original draft (lead). <bold>Damien Roos&#x02010;Weil:</bold> conceptualization (lead), data curation (equal), formal analysis (equal), methodology (lead), project administration (lead), validation (lead), writing &#x02013; original draft (lead). <bold>Magali Le Garff&#x02010;Tavernier:</bold> conceptualization (lead), data curation (equal), formal analysis (equal), methodology (lead), project administration (lead), validation (lead), writing &#x02013; original draft (lead).</p></sec><sec sec-type="COI-statement" id="jcmm70620-sec-0014"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jcmm70620-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="JCMM-29-e70620-s002.pdf"/></supplementary-material><supplementary-material id="jcmm70620-supitem-0002" position="float" content-type="local-data"><caption><p>
Data S2.
</p></caption><media xlink:href="JCMM-29-e70620-s001.pdf"/></supplementary-material></sec></body><back><ack id="jcmm70620-sec-0013"><title>Acknowledgements</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="jcmm70620-sec-0016"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jcmm70620-bibl-0001"><title>References</title><ref id="jcmm70620-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0001">
<string-name>
<given-names>S. H.</given-names>
<surname>Swerdlow</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Campo</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Pileri</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms</article-title>,&#x0201d; <source>Blood</source>
<volume>127</volume>, no. <issue>20</issue> (<year>2016</year>): <fpage>2375</fpage>&#x02013;<lpage>2390</lpage>.<pub-id pub-id-type="pmid">26980727</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0002">
<string-name>
<given-names>S. P.</given-names>
<surname>Treon</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MYD88 L265P Somatic Mutation in Waldenstr&#x000f6;m's Macroglobulinemia</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>367</volume>, no. <issue>9</issue> (<year>2012</year>): <fpage>826</fpage>&#x02013;<lpage>833</lpage>.<pub-id pub-id-type="pmid">22931316</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0003">
<string-name>
<given-names>A.</given-names>
<surname>Martinez&#x02010;Lopez</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Curiel&#x02010;Olmo</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mollejo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MYD88 (L265P) Somatic Mutation in Marginal Zone B&#x02010;Cell Lymphoma</article-title>,&#x0201d; <source>American Journal of Surgical Pathology</source>
<volume>39</volume>, no. <issue>5</issue> (<year>2015</year>): <fpage>644</fpage>&#x02013;<lpage>651</lpage>.<pub-id pub-id-type="pmid">25723115</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0004">
<string-name>
<given-names>J. J.</given-names>
<surname>Castillo</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Garcia&#x02010;Sanz</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Hatjiharissi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Recommendations for the Diagnosis and Initial Evaluation of Patients With Waldenstr&#x000f6;m Macroglobulinaemia: A Task Force From the 8th International Workshop on Waldenstr&#x000f6;m Macroglobulinaemia</article-title>,&#x0201d; <source>British Journal of Haematology</source>
<volume>175</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>77</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">27378193</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0005">
<string-name>
<given-names>J. F.</given-names>
<surname>San Miguel</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Vidriales</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Ocio</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Immunophenotypic Analysis of Waldenstrom's Macroglobulinemia</article-title>,&#x0201d; <source>Seminars in Oncology</source>
<volume>30</volume>, no. <issue>2</issue> (<year>2003</year>): <fpage>187</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">12720134</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0006">
<string-name>
<given-names>B.</given-names>
<surname>Paiva</surname>
</string-name>, <string-name>
<given-names>L. A.</given-names>
<surname>Corchete</surname>
</string-name>, <string-name>
<given-names>M.&#x02010;B.</given-names>
<surname>Vidriales</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Cellular Origin and Malignant Transformation of Waldenstr&#x000f6;m Macroglobulinemia</article-title>,&#x0201d; <source>Blood</source>
<volume>125</volume>, no. <issue>15</issue> (<year>2015</year>): <fpage>2370</fpage>&#x02013;<lpage>2380</lpage>.<pub-id pub-id-type="pmid">25655603</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0007">
<string-name>
<given-names>R.</given-names>
<surname>Garc&#x000ed;a&#x02010;Sanz</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Jim&#x000e9;nez</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Puig</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Origin of Waldenstrom's Macroglobulinaemia</article-title>,&#x0201d; <source>Best Practice &#x00026; Research. Clinical Haematology</source>
<volume>29</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>136</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">27825459</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0008">
<string-name>
<given-names>E.</given-names>
<surname>Matutes</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Owusu&#x02010;Ankomah</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Morilla</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Immunological Profile of B&#x02010;Cell Disorders and Proposal of a Scoring System for the Diagnosis of CLL</article-title>,&#x0201d; <source>Leukemia</source>
<volume>8</volume>, no. <issue>10</issue> (<year>1994</year>): <fpage>1640</fpage>&#x02013;<lpage>1645</lpage>.<pub-id pub-id-type="pmid">7523797</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0009">
<string-name>
<given-names>A.</given-names>
<surname>Gascue</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Merino</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Paiva</surname>
</string-name>, &#x0201c;<article-title>Flow Cytometry</article-title>,&#x0201d; <source>Hematology/Oncology Clinics of North America</source>
<volume>32</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>765</fpage>&#x02013;<lpage>775</lpage>.<pub-id pub-id-type="pmid">30190016</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0010">
<string-name>
<given-names>A.</given-names>
<surname>Raimbault</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Machherndl&#x02010;Spandl</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Itzykson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CD13 Expression in B Cell Malignancies Is a Hallmark of Plasmacytic Differentiation</article-title>,&#x0201d; <source>British Journal of Haematology</source>
<volume>184</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>625</fpage>&#x02013;<lpage>633</lpage>.<pub-id pub-id-type="pmid">30198568</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0011">
<string-name>
<given-names>J. J.</given-names>
<surname>Castillo</surname>
</string-name>, <string-name>
<given-names>R. H.</given-names>
<surname>Advani</surname>
</string-name>, <string-name>
<given-names>A. R.</given-names>
<surname>Branagan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Consensus Treatment Recommendations From the Tenth International Workshop for Waldenstr&#x000f6;m Macroglobulinaemia</article-title>,&#x0201d; <source>Lancet. Haematology</source>
<volume>7</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>e827</fpage>&#x02013;<lpage>e837</lpage>.<pub-id pub-id-type="pmid">33091356</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0012">
<string-name>
<given-names>F.</given-names>
<surname>Nguyen&#x02010;Khac</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Lambert</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Chapiro</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Chromosomal Aberrations and Their Prognostic Value in a Series of 174 Untreated Patients With Waldenstr&#x000f6;m's Macroglobulinemia</article-title>,&#x0201d; <source>Haematologica</source>
<volume>98</volume>, no. <issue>4</issue> (<year>2013</year>): <fpage>649</fpage>&#x02013;<lpage>654</lpage>.<pub-id pub-id-type="pmid">23065509</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0013">
<string-name>
<given-names>D.</given-names>
<surname>Krzisch</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Guedes</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Boccon&#x02010;Gibod</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cytogenetic and Molecular Abnormalities in Waldenstr&#x000f6;m's Macroglobulinemia Patients: Correlations and Prognostic Impact</article-title>,&#x0201d; <source>American Journal of Hematology</source>
<volume>96</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>1569</fpage>&#x02013;<lpage>1579</lpage>.<pub-id pub-id-type="pmid">34462944</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0014">
<string-name>
<given-names>B.</given-names>
<surname>Paiva</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Montes</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Garc&#x000ed;a&#x02010;Sanz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Multiparameter Flow Cytometry for the Identification of the Waldenstr&#x000f6;m's Clone in IgM&#x02010;MGUS and Waldenstr&#x000f6;m's Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification</article-title>,&#x0201d; <source>Leukemia</source>
<volume>28</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>166</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">23604227</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0015">
<string-name>
<given-names>D.</given-names>
<surname>Roos&#x02010;Weil</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Giacopelli</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Armand</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Identification of 2 DNA Methylation Subtypes of Waldenstr&#x000f6;m Macroglobulinemia With Plasma and Memory B&#x02010;Cell Features</article-title>,&#x0201d; <source>Blood</source>
<volume>136</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>585</fpage>&#x02013;<lpage>595</lpage>.<pub-id pub-id-type="pmid">32457988</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0016">
<string-name>
<given-names>S.</given-names>
<surname>Poulain</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Roumier</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Venet&#x02010;Caillault</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genomic Landscape of CXCR4 Mutations in Waldenstr&#x000f6;m Macroglobulinemia</article-title>,&#x0201d; <source>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</source>
<volume>22</volume>, no. <issue>6</issue> (<year>2016</year>): <fpage>1480</fpage>&#x02013;<lpage>1488</lpage>.<pub-id pub-id-type="pmid">26490317</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0017">
<string-name>
<given-names>E.</given-names>
<surname>Matutes</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Morilla</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Owusu&#x02010;Ankomah</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Houliham</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Meeus</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Catovsky</surname>
</string-name>, &#x0201c;<article-title>The Immunophenotype of Hairy Cell Leukemia (HCL). Proposal for a Scoring System to Distinguish HCL From B&#x02010;Cell Disorders With Hairy or Villous Lymphocytes</article-title>,&#x0201d; <source>Leukemia &#x00026; Lymphoma</source>
<volume>14</volume>, no. <issue>Suppl 1</issue> (<year>1994</year>): <fpage>57</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">7820054</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0018">
<string-name>
<given-names>I.</given-names>
<surname>Del Giudice</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Matutes</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Morilla</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Diagnostic Value of CD123 in B&#x02010;Cell Disorders With Hairy or Villous Lymphocytes</article-title>,&#x0201d; <source>Haematologica</source>
<volume>89</volume>, no. <issue>3</issue> (<year>2004</year>): <fpage>303</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">15020268</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0019">
<string-name>
<given-names>R.</given-names>
<surname>Alaggio</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Amador</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Anagnostopoulos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms</article-title>,&#x0201d; <source>Leukemia</source>
<volume>36</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>1720</fpage>&#x02013;<lpage>1748</lpage>.<pub-id pub-id-type="pmid">35732829</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0020">
<string-name>
<given-names>L.</given-names>
<surname>Miguet</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Lennon</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Baseggio</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cell&#x02010;Surface Expression of the TLR Homolog CD180 in Circulating Cells From Splenic and Nodal Marginal Zone Lymphomas</article-title>,&#x0201d; <source>Leukemia</source>
<volume>27</volume>, no. <issue>8</issue> (<year>2013</year>): <fpage>1748</fpage>&#x02013;<lpage>1750</lpage>.<pub-id pub-id-type="pmid">23302770</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0021">
<string-name>
<given-names>C.</given-names>
<surname>Mayeur&#x02010;Rousse</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Guy</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Miguet</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CD180 Expression in B&#x02010;Cell Lymphomas: A Multicenter GEIL Study</article-title>,&#x0201d; <source>Cytometry. Part B, Clinical Cytometry</source>
<volume>90</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>462</fpage>&#x02013;<lpage>466</lpage>.<pub-id pub-id-type="pmid">26384474</pub-id>
</mixed-citation></ref><ref id="jcmm70620-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jcmm70620-cit-0022">
<string-name>
<given-names>C.</given-names>
<surname>Boccon&#x02010;Gibod</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Sourdeau</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Morel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Circulating Tumor Cells in Waldenstr&#x000f6;m Macroglobulinemia</article-title>,&#x0201d; <source>Leukemia</source>
<volume>38</volume> (<year>2024</year>): <fpage>903</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">38332185</pub-id>
</mixed-citation></ref></ref-list></back></article>